Quantum Cyber N V's Comment on Sales, Marketing and Customers
The company operates in the disease diagnosis market, specializing in genetic diagnostic technologies aimed at earlier and more accurate detection. It was developing colorectal cancer screening products, including ColoAlert and next-generation colorectal cancer screening candidates, but discontinued these products in February 2026. The company continues to pursue commercialization of a blood-based pancreatic cancer detection product candidate. Additionally, it is expanding its business focus into post-quantum cybersecurity. The company is headquartered in Mainz, Germany, and employed approximately 10 full-time and 3 part-time staff as of March 30, 2026. Customers include PharmGenomics GmbH.
Mainz Biomed, an innovative biotechnology company focused on the development of solutions for colorectal cancer detection, has announced a significant agreement with Quest Diagnostics. This partnership aims to provide essential clinical trials laboratory services that will bolster the development of Mainz Biomed’s groundbreaking screening test.Colorectal cancer is one of the leading causes of cancer-related deaths globally, and the demand for effective screening solutions continues to rise. Traditional methods of detection can often be invasive, inconvenient, or lead to false positives. In response to this urgent public health need, Mainz Biomed has been diligently working on a non-invasive genetic test th...
Quantum Cyber N V’s Comment on Sales, Marketing and Customers
The company operates in the disease diagnosis market, specializing in genetic diagnostic technologies aimed at earlier and more accurate detection. It was developing colorectal cancer screening products, including ColoAlert and next-generation colorectal cancer screening candidates, but discontinued these products in February 2026. The company continues to pursue commercialization of a blood-based pancreatic cancer detection product candidate. Additionally, it is expanding its business focus into post-quantum cybersecurity. The company is headquartered in Mainz, Germany, and employed approximately 10 full-time and 3 part-time staff as of March 30, 2026. Customers include PharmGenomics GmbH.
Sources:
Quantum Cyber N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Quantum Cyber N v’s corporate clients.
For your research, we’ve provided 9 tables on Quantum Cyber N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
